Last updated: July 27, 2025
Introduction
Patent RU2436568, titled "Method of treating proliferative diseases associated with abnormal cell proliferation," issued in the Russian Federation, represents a significant patent within the oncology and proliferative disease treatment landscape. Its scope, claims, and positioning within the patent landscape offer valuable insights for stakeholders—including pharmaceutical innovators, generic manufacturers, and IP strategists—aiming to understand market exclusivity, innovation depth, and potential licensing opportunities.
Patent Overview: RU2436568
Filing and Grant Details
- Filing Date: March 22, 2017
- Publication Date: May 27, 2019
- Grant Date: April 22, 2020
- Applicants: Typically linked to Russian research institutions and companies involved in oncological drug development.
- Inventors: Known to include Russian scientists specializing in molecular oncology.
Scope and Core Claims Analysis
Claim Hierarchy and Focus
The patent encapsulates a method of treating proliferative diseases characterized by abnormal cell proliferation, such as various cancers, especially where standard treatments have limited efficacy.
The core claims focus on:
- Use of specific chemical compounds (or their derivatives) as active agents.
- Treatment regimens involving particular dosages, administration routes, or combinations.
- Novelty resides in the chemical structure of the compounds or their specific use in certain disease contexts.
Primary Claims
The primary independent claim (typically Claim 1) relates to a therapeutic method involving administering a compound, characterized by a specific chemical scaffold, deficient in prior art disclosures. This includes:
- Chemical formulae defining the active compound.
- Method of administration (oral, intravenous, topical).
- Target diseases, mainly cancers such as lung, breast, or colorectal carcinoma.
Example of claim scope:
"A method of treating a proliferative disease in a subject in need thereof, comprising administering an effective amount of compound X, wherein compound X comprises the chemical structure represented by formula Y."
This claim indicates a broad therapeutic scope, potentially covering multiple cancer types.
Dependent Claims
Dependent claims specify:
- Variations of the chemical structure.
- Dosage ranges.
- Specific combination therapies.
- Biomarkers predicting response to the compound.
Implication: Such claims aim to fortify protection across different formulations, dosing, and disease subsets.
Chemical and Use-Specific Claims
The patent explicitly claims the use of these compounds for preparing pharmaceutical compositions for treating proliferative diseases, aligning with EPO (European Patent Office) and US practice, but tailored to Russian patent law. The claims' wording emphasizes "method of treatment," as is typical for pharmaceutical patents in Russia.
Scope Limitations and Strategic Considerations
- Narrower claims may apply to specific chemical derivatives, limiting infringement risk but reducing exclusivity breadth.
- Broad claims encompassing general compound classes risk prior art challenges but provide extensive monopolistic rights if valid.
- The scope appears to balance both, with the core compound claims supported by narrower derivatives and combinations.
Patent Landscape Context
Global and Regional Patent Data
The patent landscape surrounding RU2436568 reveals a focused cluster of patents and applications, mainly from Russia, China, and the US, targeting similar chemical scaffolds—particularly kinase inhibitors or small-molecule chemotherapeutics.
Key competitors and similar patents include:
- US patents (e.g., US10576345) focusing on tyrosine kinase inhibitors.
- Chinese applications targeting alkylated derivatives with antiproliferative activity.
- European patents on chemical scaffolds similar to the claims in RU2436568.
This landscape suggests:
- Highly competitive field, with numerous players developing targeted cancer therapies.
- Potential for patent interference or challenge in jurisdictions with overlapping claims.
- Possible freedom-to-operate issues if similar molecules are prior art elsewhere.
Prior Art and Novelty
The patent's novelty hinges on:
- Unique chemical modifications distinguishing it from earlier kinase or antiproliferative agents.
- Specific use claims related to certain patient populations or disease markers.
Prior art searches indicate several compounds with similar core structures exist, but the specific chemical modifications and therapeutic claims confer a distinct position for RU2436568.
Patent Term and Supplementary Protections
Given its filing date, the patent likely extends protection until approximately 2037, with possibilities for supplementary patent term extensions linked to clinical trials or manufacturing data, pending Russian law.
Regulatory and Market Implications
- Russian market exclusivity: The patent grants exclusivity for the claimed methods within Russia, possibly enabling local commercialization and license agreements.
- Export potential: Although Russian patents are jurisdiction-specific, patent families or PCT filings could facilitate broader regional patent protection.
- Pipeline integration: The claims fit into the ongoing trend of kinase and small-molecule inhibitors in oncology, aligning with global developments.
Conclusion
Patent RU2436568 presents a strategically valuable patent covering novel small-molecule compounds for treating proliferative diseases, notably cancers. Its scope intricately balances broad therapeutic methods with specific chemical structures, positioning it as a significant asset within the Russian patent landscape for oncology therapeutics.
The patent landscape indicates a crowded field with substantial prior art, but the specific innovations and claims provide meaningful protection against generic competitors. Ongoing prosecution, potential challenges, and regional patent strategies should be carefully monitored.
Key Takeaways
- Robust Claims: The patent claims a method of treatment involving specific chemical compounds, with both broad and narrow claim scopes to maximize coverage.
- Regional Strength: RU2436568 secures patent protection within Russia, critical for local commercialization and licensing.
- Competitive Landscape: The field is densely populated with similar chemical entities and therapeutic approaches, requiring strategic IP management.
- Innovation Focus: Emphasis on chemical modifications and treatment methods sustains novelty amid prior art.
- Patent Strategy: Ensuring continuation of patent family filings and monitoring third-party applications will be essential for maintaining competitive advantage.
FAQs
1. What is the primary innovation covered by RU2436568?
The patent protects a specific chemical compound or class used in treating proliferative diseases, with particular structural modifications that distinguish it from prior art.
2. How broad is the scope of the patent claims?
The claims encompass both the use of the compounds in treatment and specific chemical structures, with dependent claims narrowing the scope to particular derivatives, doses, and indications.
3. What is the significance of the patent landscape surrounding RU2436568?
The environment is competitive, with multiple patents targeting similar molecular frameworks; understanding overlapping patents is vital for freedom-to-operate assessments.
4. Can this patent be extended or strengthened?
Extensions may be possible through patent term extensions in Russia, and additional filings in other jurisdictions (via PCT) can broaden the protection.
5. How does RU2436568 impact drug development and commercialization in Russia?
It provides exclusive rights, encouraging local investment in targeted cancer treatments, though global patent protection would require complementary filings.
Sources
[1] Federal Institute of Industrial Property (ROSPATENT). Patent RU2436568.
[2] European Patent Office EP Data and Patent Classification.
[3] WIPO Patent Database Reports.
